If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Subjects prescribed abacavir/lamivudine tablets","arm_group_description":"Patients with HIV to whom abacavir/lamivudine tablets are administered (prescribed).","arm_type":""}],"assignment":"","brief_summary":"This post-marketing surveillance (PMS) collected safety data of EPZICOM Tablets administered in the Japanese pregnant and parturient women target population per the requirements of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). (\"EPZICOM\" is a trademark of the GlaxoSmithKline group of companies.)","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Special Drug Use Investigation for EPZICOM® (abacavir sulfate/lamivudine) tablet (Pregnancy) (HRD Cooperative Investigation)","conditions":[{"DisplayValue":"Immune, Inflammatory & Infections - Other","DisplayValue_OneLinkTx":"","InternalValue":"CON_IMMUNE_OTHER","LookupValue":"Virus Diseases","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:10:28","criteria":"Inclusion Criteria: - Subjects who are pregnant or parturient - Subjects who are treated with abacavir/lamivudine Exclusion Criteria: - None","detailed_description":"","display_gender":"Female","display_gender_internal":"GENDER_FEMALE","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"1","exclusion":"","gender":"Female","gender_based":"","gender_description":"","healthy_volunteers":"none","id":"2b3445ba-e149-5d90-a6f7-93d13cd2a191","internal":{"content":null,"contentDigest":"50ec533a5ad69782b0b73a1629330b8b","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Subjects who are pregnant or parturient - Subjects who are treated with abacavir/lamivudine Exclusion Criteria: - None","interventions":[{"arm_group_label":"Subjects prescribed abacavir/lamivudine tablets","intervention_description":"Administered according to the locally approved label","intervention_name":"abacavir/lamivudine tablets","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["HIV Infection"],"last_follow_up_date":"12/01/2010 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":null,"minimum_age_raw":"","modified_date":"10/01/2018 22:21:44","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"Case-Only","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Special Drug Use Investigation for EPZICOM® (abacavir sulfate/lamivudine) tablet (Pregnancy) (HRD Cooperative Investigation)","org_study_id":"112348","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["Japan: Pharmaceuticals and Medical Devices Agency"]},"phase":"phase 4","primary_compl_date":"12/01/2010 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Number of subjects with adverse events","outcome_time_frame":"up to 6 years","outcome_safety_issue":"True"}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"04/01/2010 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"112348"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}